Journal for Immunotherapy of Cancer
Overview
The Journal for Immunotherapy of Cancer is a peer-reviewed publication dedicated to advancing the field of cancer immunotherapy. It provides a platform for researchers, clinicians, and scientists to share their latest findings, clinical trials, and innovative approaches in harnessing the immune system to treat and prevent cancer. With a focus on immunotherapeutic strategies, this journal aims to accelerate the development of effective and personalized cancer treatments.
Details
Details
Abbr.
J Immunother Cancer
Start
2013
End
Continuing
e-ISSN
2051-1426
Country
United Kingdom
Language
English
Specialties
Oncology
Pharmacology
Allergy & Immunology
Pharmacology
Allergy & Immunology
Metrics
Metrics
h-index / Ranks: 2345
117
SJR / Ranks: 409
3728
CiteScore / Ranks: 508
16.80
JIF / Ranks: 401
10.9
Recent Articles
11.
Abdulrahman Z, Slieker R, McGuire D, Welters M, van Poelgeest M, van der Burg S
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40081939
Background: The tumor microenvironment (TME) is a complex and dynamic ecosystem that is known to influence responses to immunotherapy. We leveraged single-cell spatial transcriptomics to systematically dissect the intricate complexity...
12.
Grandits M, Palhares L, Osborn G, Chauhan J, Stoker K, Sow H, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40074330
Background: Anti-human epidermal growth factor receptor 2 (HER2) IgG1-based antibody therapies significantly improve cancer prognosis, yet intrinsic or acquired resistance to fragment antigen-binding (Fab)-mediated direct effects commonly occurs. Most resistant...
13.
Cottrell T, Lotze M, Ali A, Bifulco C, Capitini C, Chow L, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40054999
Immunotherapy of cancer is now an essential pillar of treatment for patients with many individual tumor types. Novel immune targets and technical advances are driving a rapid exploration of new...
14.
Jeong H, Koh J, Kim S, Yim J, Song S, Kim H, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40050048
Background: Some patients with non-small-cell lung cancer (NSCLC) benefit from immune checkpoint inhibitors (ICIs) despite programmed death-ligand 1 (PD-L1) expression. To address the mechanism of ICI resistance in PD-L1-positive NSCLC,...
15.
Moore J, Gkantalis J, Guix I, Chou W, Yuen K, Lazar A, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40050047
Background: The efficacy of immune checkpoint blockade (ICB) depends on restoring immune recognition of cancer cells that have evaded immune surveillance. Transforming growth factor-beta (TGFβ) is associated with immune-poor, so-called...
16.
Lin H, Hua J, Wang Y, Chen M, Liang Y, Yan L, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40050046
Background: Current prognostic and predictive biomarkers for lung adenocarcinoma (LUAD) predominantly rely on unimodal approaches, limiting their characterization ability. There is an urgent need for a comprehensive and accurate biomarker...
17.
Zang H, Liu T, Wang X, Cheng S, Zhu X, Huang C, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40050045
Background: The programmed cell death 1 (PD-1) is an immune checkpoint that mediates immune evasion of tumors. Alternative splicing (AS) such as intron retention (IR) plays a crucial role in...
18.
19.
Liu M, Qian M, Sun W, Sun X, Sun Y, Yu M, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40050043
Background: Patients with liver metastases of triple-negative breast cancer (TNBC) show poor prognosis compared with other metastases. Chemotherapy is the primary treatment for advanced TNBC. Tumor cell diversity and the...
20.